表紙
市場調査レポート

特発性 (本態性) 高血圧症:世界の治験レビュー

Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2014

発行 GlobalData 商品コード 247625
出版日 ページ情報 英文 113 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
特発性 (本態性) 高血圧症:世界の治験レビュー Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2014
出版日: 2014年09月21日 ページ情報: 英文 113 Pages
概要

原因不明の高血圧は、特発性高血圧症と呼ばれ、高血圧症の95%を占めます。高血圧につながる原因因子が患者によって異なる障害です。 特発性高血圧の症侯は、頭痛、鼻血、息切れ、倦怠感、胸痛などです。診断には、身体検査、血圧測定、尿検査、血液検査、心電図などを用います。治療は血圧のレベルによって行い、薬物療法と生活習慣の改善が主なものです。 合併症には、アテローム性動脈硬化症、心臓発作、脳卒中、心臓肥大、腎臓障害などがあります。

当レポートでは、特発性 (本態性) 高血圧症による疼痛に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、G7およびE7諸国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んで、お届けします。

イントロダクション

  • 特発性 (本態性) 高血圧症 について
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • 上位5ヶ国における治験件数; アジア太平洋地域
    • 上位5ヶ国における治験件数; 欧州
    • 主要国における治験件数; 北米
    • 上位5ヶ国における治験件数; 中東/アフリカ地域
    • 上位5ヶ国における治験件数; 中南米

G7諸国における治験件数: 特発性 (本態性) 高血圧症 治験件数の心臓血管治験件数に対する比率

フェーズ(相)別治験件数: G7諸国

G7諸国における治験件数:フェーズ(相)別

E7諸国における治験件数: 特発性 (本態性) 高血圧症 治験件数の心臓血管治験件数に対する比率

フェーズ(相)別治験件数: E7諸国

E7諸国における治験件数:フェーズ(相)別

フェーズ(相)別治験件数

  • フェーズ(相)別の進行中治験件数

進捗状況別の治験件数

評価項目別の治験件数

未完了の治験

一定期間に採用された被験者数

スポンサーの種類別の治験件数

有望なスポンサー

治験主要参加企業 - 特発性 (本態性) 高血圧症 治療薬

有望な薬剤

治験のプロファイル

  • 代表的な企業の治験の概要
    • Novartis AG
    • C. H. Boehringer Sohn AG & Co. KG
    • 武田薬品工業
    • 第一三共
    • Merck & Co., Inc.
    • Medionics International Inc
    • Bayer AG
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Les Laboratoires Servier SAS
  • 代表的な研究機関病院の治験の概要
    • Institut de Recherches Internationales Servier
    • Regional Hospital Holstebro
    • National Heart, Lung, and Blood Institute
    • University of Erlangen-Nurnberg
    • University of Pavia
    • St. George's University of London
    • Central South University
    • 愛媛大学大学院医学系研究科
    • 菰野厚生病院
    • 岡山大学大学院医歯薬学総合研究科

5大治験プロファイル

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

GlobalData's clinical trial report, "Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2014" provides data on the Idiopathic (Essential) Hypertension clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Idiopathic (Essential) Hypertension. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Idiopathic (Essential) Hypertension. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Idiopathic (Essential) Hypertension
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Idiopathic (Essential) Hypertension
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Idiopathic (Essential) Hypertension Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • C. H. Boehringer Sohn AG & Co. KG
      • Clinical Trial Overview of C. H. Boehringer Sohn AG & Co. KG
      • Takeda Pharmaceutical Company Limited
      • Clinical Trial Overview of Takeda Pharmaceutical Company Limited
      • Daiichi Sankyo Company, Limited
      • Clinical Trial Overview of Daiichi Sankyo Company, Limited
      • Merck & Co., Inc.
      • Clinical Trial Overview of Merck & Co., Inc.
      • Medionics International Inc
      • Clinical Trial Overview of Medionics International Inc
      • Bayer AG
      • Clinical Trial Overview of Bayer AG
      • GlaxoSmithKline plc
      • Clinical Trial Overview of GlaxoSmithKline plc
      • Pfizer Inc.
      • Clinical Trial Overview of Pfizer Inc.
      • Les Laboratoires Servier SAS
      • Clinical Trial Overview of Les Laboratoires Servier SAS
    • Clinical Trial Overview of Top Institutes / Government
      • Institut de Recherches Internationales Servier
      • Clinical Trial Overview of Institut de Recherches Internationales Servier
      • Regional Hospital Holstebro
      • Clinical Trial Overview of Regional Hospital Holstebro
      • National Heart, Lung, and Blood Institute
      • Clinical Trial Overview of National Heart, Lung, and Blood Institute
      • University of Erlangen-Nurnberg
      • Clinical Trial Overview of University of Erlangen-Nurnberg
      • University of Pavia
      • Clinical Trial Overview of University of Pavia
      • St. George's University of London
      • Clinical Trial Overview of St. George's University of London
      • Central South University
      • Clinical Trial Overview of Central South University
      • Ehime University Graduate School of Medicine
      • Clinical Trial Overview of Ehime University Graduate School of Medicine
      • Komono Kosei Hospital
      • Clinical Trial Overview of Komono Kosei Hospital
      • Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
      • Clinical Trial Overview of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Region, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014*
  • Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials, G7 Countries (%), 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials, E7 Countries (%), 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Idiopathic (Essential) Hypertension Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG & Co. KG, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Medionics International Inc, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Les Laboratoires Servier SAS, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Institut de Recherches Internationales Servier, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Regional Hospital Holstebro, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Erlangen-Nurnberg, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pavia, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by St. George's University of London, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Central South University, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Ehime University Graduate School of Medicine, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Komono Kosei Hospital, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials Market, Global, Clinical Trials by Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2014*

List of Figures

  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014*
  • Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials, G7 Countries (%), 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials, E7 Countries (%), 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Idiopathic (Essential) Hypertension Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top